Tuesday October 17th 2017

Brazil’s ANVISA approves Genzyme’s Lemtrada for multiple sclerosis treatment

Genzyme, a Sanofi company, announced today that Brazil’s national health surveillance agency, ANVISA, has approved Lemtrada (alemtuzumab) for the treatment of patients with relapsing forms of multiple sclerosis (MS) to slow or reverse the accumulation of physical disability and reduce the frequency of clinical exacerbations.

Read original article:  

Brazil’s ANVISA approves Genzyme’s Lemtrada for multiple sclerosis treatment

Leave a Comment

More from category

Roche to present new OCREVUS (ocrelizumab) efficacy and safety data in relapsing and primary progressive forms of multiple sclerosis at ECTRIMS
Roche to present new OCREVUS (ocrelizumab) efficacy and safety data in relapsing and primary progressive forms of multiple sclerosis at ECTRIMS

Roche announced today that new data on OCREVUS ® (ocrelizumab) in people with relapsing and primary progressive forms [Read More]

All you need to know about dysesthesia
All you need to know about dysesthesia

Dysesthesia is a painful, itchy sensation, often associated with multiple sclerosis (MS). Learn more about the symptoms [Read More]

Medical News Today: All you need to know about dysesthesia
Medical News Today: All you need to know about dysesthesia

Dysesthesia is a painful, itchy sensation, often associated with multiple sclerosis (MS). Learn more about the symptoms [Read More]

MRI brain scans can reveal MS risk in children before clinical symptoms appear
MRI brain scans can reveal MS risk in children before clinical symptoms appear

By the time multiple sclerosis (MS) is diagnosed in children, it may be difficult to prevent the disabilities and [Read More]

Open Enrollment for Marketplace and Medicare Plans
Open Enrollment for Marketplace and Medicare Plans

/About-the-Society/News/Open-Enrollment-for-Marketplace-and-Medicare-Plans [Read More]